Incidence and costs of adverse drug reactions in a tertiary care pediatric intensive care unit

Journal of Clinical Pharmacology

Volumn 53, Issue 5, 2013, Pages 567-573

  Du, Wei ^a   Lehr, Victoria Tutag ^b   Caverly, Mary ^c   Kelm, Lauren ^c   Reeves, Jaxk ^d   Lieh Lai, Mary ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^d UNIVERSITY OF GEORGIA   (United States)

Author keywords

Adverse drug reaction; Costs; Incidence; Length of stay; Pediatric intensive care unit; Risk factors

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BARBITURIC ACID DERIVATIVE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ELECTROLYTE; IMMUNOGLOBULIN; INSULIN; OPIATE; PROSTAGLANDIN;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION; ANAPHYLAXIS; ARTICLE; CARDIOVASCULAR SURGERY; CHILD; COST OF ILLNESS; DISEASE SURVEILLANCE; DISORDERS OF ACID BASE BALANCE; ELECTROLYTE DISTURBANCE; FEMALE; FLUSHING; HEART ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTENSION; HYPOVENTILATION; INTENSIVE CARE UNIT; LENGTH OF STAY; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; PRESCHOOL CHILD; PROSPECTIVE STUDY; SCHOOL CHILD; STEVENS JOHNSON SYNDROME; TERTIARY HEALTH CARE; UNSPECIFIED SIDE EFFECT; URTICARIA;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DRUG TOXICITY; FEMALE; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; INCIDENCE; INFANT; INTENSIVE CARE UNITS, PEDIATRIC; LENGTH OF STAY; MALE; RISK FACTORS; TERTIARY CARE CENTERS;

EID: 84880149848     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.75     Document Type: Article

References (40)

1. Lucado J, Paez K, Elixhauser A. Medication-related adverse outcomes in U.S. Hospitals and Emergency Departments, 2008. Healthcare utilization project, statistical brief #109. NEISS-CADES 2001 report U.S.
2. Aagaard L, Christensen A. Information about adverse drug reactions reported in children: a qualitative review of empirical studies. B J Clin Pharmacol. 2010;70(4):481-491.
3. Tundia NL, Heaton PC, Kelton ML. The national burden of E-codeidentified adverse drug events among hospitalized children using a national discharge database. Pharmacoepidemiol Drug Saf. 2011; 20(8):866-878.
4. Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med. 1995;155(18):1949-1956.
5. Bates DW, Evans RS, Murff H, Stetson PD, Pizziferri L, Hripcsak G. Detecting adverse events using information technology. J Am Med Inform Assoc. 2003;10(2):115-128. (Pubitemid 36397587)
6. Leeder JS. Developmental and pediatric pharmacogenomics. Pharmacogenomics. 2003;4(3):331-341. (Pubitemid 36546613)
7. Kearns GL, Abel-Rahman SM, Alander SW, et al. Developmental pharmacology - drug disposition, action and therapy in infants and children. N Engl J Med. 2003;349:1157-1167. (Pubitemid 37122329)
8. Kaushal R, Bates DW, Landrigan C, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA. 2001;285(16): 2114-2120. (Pubitemid 32367829)
9. Clavenna A, Bonati M. Drug prescriptions to outpatient children: a review of the literature. Eur J Clin Pharmacol. 2009; (65):749-755.
10. Carleton BC, Smith MA, Gelin MN, Heathcote SC. Paediatric adverse drug reaction reporting: understanding and future directions. Can J Clin Pharmacol. 2007;14(1):e45-e57.
11. Aagaard L, Weber CB, Hansen EH. Adverse drug reactions in the paediatric population in Denmark: a retrospective analysis of reports made to the Danish Medicines Agency from 1998 to 2007. Drug Saf. 2010;33(4):327-339.
12. Clavenna A, Berti A, Gualandi L, Rossi E, De Rosa M, Bonati M. Drug utilisation profile in the Italian paediatric population. Eur J Pediatr. 2009;168(2):173-180.
13. Clavenna A, Bonati M. Adverse drug reactions in childhood: a review of prospective studies and safety alerts. Arch Dis Child. 2009;94(9):724-728.
14. Haffner S, von Laue N, Wirth S, Thurman PA. Detecting adverse drug reactions on paediatric wards: intensified surveillance versus computerized screening of laboratory values. Drug Saf. 2005;28(5): 453-464. (Pubitemid 40733731)
15. Le J, Nguyen T, Law AV, Hodding J. Adverse drug reactions among children over a 10-year period. Pediatrics. 2006;118(2):555-562. (Pubitemid 46085410)
16. Takata GS, Takemoto CK, Waite S. Characteristics of medication errors and adverse drug events in hospitals participating in the California Pediatric Patient Safety Initiative. Am J Health Sys Pharm. 2008;65:2036-2044.
17. Oehme A-K, Rashed AN, Hfele B, Wong ICK, Rascher W, Neubert A. Adverse drug reactions in hospitalized children in Germany are decreasing: results of a nine year cohort-based comparison. PLoS ONE. 2012;7(9):e44349. DOI: 10.1371/journal.phone.0044349
18. Rashed AN, Wong ICK, Cranswick N, et al. Adverse Drug Reactions in Children - International Surveillance and Evaluation (ADVISE). Drug Saf. 2012;35(6):481-494.
19. Farrokhi S, Pourpak Z, Fatthai F, et al. Adverse drug and medical instrument reactions in a pediatric intensive care unit. Pharmacoepidemiol Drug Saf. 2009;18:761-762.
20. Telechea H, Speranza N, Lucas L, Giachetto G, Nanni L, Menchaca A. Adverse drug reactions in a paediatric intensive care unit. Farm Hosp. 2012;36(5):403-409. DOI: 10.1016/j.farma.2011.08.007: Epub 2012 Aug 4.
21. Turner S, Nunn AJ, Fielding K, Choonara I. Adverse drug reactions to unlicensed and off-label drugs on pediatric wards. Acta Paediatr. 1999;88:965-968. (Pubitemid 29448261)
22. Agarwal S. Prevalence of adverse events in pediatric intensive care units in the United States. Pediatr Crit Care Med. 2010;11(5):568.
23. Smitt JHS, van Woensel JBM, Bos AP. Skin lesions in children admitted to the paediatric intensive care unit. Eur J Paediatr. 2011;170:1263-1265.
24. Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289(9):1107-1116. (Pubitemid 37430324)
25. Ross CJ, Carleton B, Warn DG, Stenton SB, Rassekh SR, Hayden MR. Genotypic approaches to therapy in children: a national active surveillance network (GATC) to study the pharmacogenomics of severe adverse drug reactions in children. Ann N Y Acad Sci. 2007;1110:177-192. (Pubitemid 350043007)
26. Lasky T, Ernst FR, Greenspan J, Wang S, Gonzalez L. Estimating pediatric inpatient medication use in the United States. Pharmacoepidemiol Drug Saf. 2011;20:76-82.
27. Choonara I, Rieder MJ. Drug Toxicity and Adverse Drug Reactions in Children - A Brief Historical Review. Nottingham, United Kingdom: Nottingham University Press; 2004.
28. Gill AM, Leach HJ, Hughes J, et al. Adverse drug reactions in a paediatric intensive care unit. Acta Paediatr. 1995;84(4):438-441.
29. Carelton BC, Poole RL, Smith MA, Leeder JS, et al. Adverse drug reaction surveillance: developing a national network in Canada's children's hospitals. Pharmacoepidemiol Drug Saf. 2009;18:713- 721.
30. Fabiano V, Marneli C, Zuccotti GV. Adverse drug reactions in newborns, infants and toddlers: pediatric pharmacovigilance between present and future. Expert Opin Drug Saf. 2010;11(1): 95-105. Epub 2011 May 9.
31. Takata GS, Mason W, Taketomo C, Logsdon T, Sharek PJ. Development, testing, and findings of a pediatric-focused trigger tool to identify medication-related harm in US children's hospitals. Pediatrics. 2008;121(4):e927-935.
32. Castello FV, Cassano A, Gregory P, Hammond J. The Pediatric Risk of Mortality (PRISM) score and Injury Severity Score (ISS) for predicting resource utilization and outcome of intensive care in pediatric trauma. Crit Care Med. 1999;27(5):985-988. (Pubitemid 29266019)
33. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49:2229-2232.
34. American Academy of Pediatrics Steering Committee on Quality Improvement and Management and Committee on Hospital Care. Policy statement - principles of pediatric patient safety: reducing harm due to medical care. Pediatrics. 2011;127:1199-1210.
35. Finney DJ. The design and logic of a monitor of drug use. J Chronic Dis. 1965;18:77-98.
36. Castro-Pastrana LI, Carleton B. Mechanisms and surveillance of drug safety symposium. J Popul Ther Clin Pharmacol. 2011;18(1): e76-e88.
37. Thurman PA. Methods and systems to detect adverse drug reactions in hospitals. Drug Saf. 2001;24:961-968.
38. Osihikoya KA, Chukwura H, Njokanma OF, Sanbanjo IO, Ojo I. Incidence and cost estimate of treating pediatric adverse drug reactions in Lagos, Nigeria. Sao Paulo Med. 2011;129(3):153-164.
39. Aranda JV. Factors associated with adverse drug reactions in the newborn. Pediatr Pharmacol. 1983;3(3-4):245-249. (Pubitemid 14102408)
40. Rashed AN, Wong ICK, Cranswick N, Tomlin S, Rascher W, Neubert A. Risk factors associated with adverse drug reactions in hospitalized children: international multicentre study. Eur J Clin Pharmacol. 2012;68:801-810.